The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Does The Forecasted Market Size Of The Soliris Market Compare Between 2026 And 2030?
The soliris market size has shown significant growth in recent years. It is forecast to expand from $2030.44 million in 2025 to $2191.9 million in 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. This historical expansion can be attributed to several factors, including unmet needs in rare diseases, successful clinical outcomes in pnh and ahus, regulatory orphan drug incentives, improved patient survival rates, and a limited number of therapeutic alternatives.
The soliris market size is projected to experience substantial expansion over the next few years. By 2030, it is forecast to reach $2941.58 million, growing at a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period is primarily driven by the market’s expansion into more complement-mediated diseases, a heightened awareness of rare diseases, advancements in genetic diagnostics, increased healthcare funding allocated for orphan drugs, and the implementation of long-term therapy adherence programs. Significant trends expected in the forecast period include the increasing adoption of complement inhibitor therapies, a growing focus on ultra-rare diseases, the broader application of long-term biologic treatments, a rise in genetic testing for rare disorders, and the overall growth of the high-value orphan drug market.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp
What Are The Main Drivers Accelerating The Growth Of The Soliris Market?
The expanding occurrence of rare blood conditions is projected to boost the growth of the Soliris market in the future. These conditions are unusual ailments impacting the blood’s formation, constituents, or coagulation, including examples like hemophilia, sickle cell anemia, and thalassemia. This increased prevalence stems from better diagnostic methods, heightened awareness, and genetic along with environmental influences. Soliris functions by inhibiting the complement protein C5, thereby assisting patients with rare blood disorders by hindering excessive complement activation. This action lessens the chance of serious issues like hemolysis and organ damage, consequently enhancing overall disease management and patient results. As an illustration, data from May 2024 by the National Health Service (NHS) England, a government-funded healthcare provider in the UK, indicated that roughly 17,000 individuals in England suffer from sickle cell disease, a hereditary blood disorder, with about 250 new diagnoses each year. Consequently, the rising incidence of rare blood disorders is fueling the expansion of the Soliris market. Future expansion of the Soliris market is anticipated to be driven by increasing investments in research on rare diseases. This surge in research funding for rare diseases stems from a growing acknowledgment of unaddressed medical requirements, progress in genomics, and the promise of innovative treatments capable of enhancing patient results. Such investments benefit Soliris by deepening comprehension of conditions that lack adequate treatment, thus stimulating greater demand for efficacious therapies. For example, in July 2023, the Department of Health and Social Care, a UK government body, allocated substantial funding, comprising USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, which links genetic information with clinical characteristics across 50 rare diseases to improve diagnostic and treatment development. Hence, the increasing financial commitment to rare disease research is a key factor propelling the Soliris market’s expansion.
Which Segment-Based Categories Are Covered In The Soliris Market?
The soliris market covered in this report is segmented –
1) By Type: Plasma Exchange, Plasma Infusion
2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Which Trends Are Influencing The Expansion Of The Soliris Market?
The primary direction within the soliris market involves concentrating on the development of biologic medications for neuromyelitis optica spectrum disorder (NMOSD), intended to improve therapeutic choices for rare blood conditions. This signifies a considerable stride in managing NMOSD, a seldom-seen and debilitating autoimmune disease that targets the central nervous system, by providing an effective therapy designed to minimize relapses and prevent additional neurological damage. For example, in October 2023, AstraZeneca PLC, a pharmaceutical enterprise headquartered in the UK, obtained approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China. This was for the care of adult patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who exhibit positivity for anti-aquaporin-4 (AQP4) antibodies (Ab+). This particular approval establishes Soliris as the initial and only complement inhibitor sanctioned for NMOSD treatment across China.
Which Industry Players Are Present In The Soliris Market?
Major companies operating in the soliris market are Pfizer
Access The Complete Soliris Market Report:
https://www.thebusinessresearchcompany.com/report/soliris-global-market-report
Which Region Holds The Largest Share In The Soliris Market?
North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model